Beta-alanine supplementation in patients with COPD receiving non-linear periodized exercise (NLPE) training: randomized placebo-controlled trial.

• Conditions: Chronic obstructive pulmonary disease (COPD); Exercise intolerance; Muscle dysfunction.

• Registration Number: NL-OMON23943
• Lead Sponsor: Radboudumc Board of Directors

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 154

Inclusion Criteria

COPD, GOLD group B or D
- Modified Medical Research Council (mMRC) dyspnoea score =2
- Clinically stable according to the pulmonary physician, i.e. no exacerbation and/or hospitalization within the previous 4 weeks.
- Age between 40-80 years
- Attending the regular in- or outpatient pulmonary rehabilitation program in Dekkerswald or CIRO and receiving NPLE

Exclusion Criteria

Patients will be excluded if they meet at least one of the following criteria: instable cardiac disease, use of anabolic steroids during PR program, history of drugs/alcohol abuse, vegetarianism, inability to understand the Dutch language, self-reported beta-alanine supplementation in the past 3 months, participation in a PR program within the past 12 months, inability to perform an incremental shuttle walk test.

If the patient agrees to undergo a vastus lateralis muscle biopsy, the following exclusion criterion will also apply: bleeding disorder, a recent trauma of the muscle, or an infection in the region of the proposed biopsy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exercise tolerance, defined as walk endurance time. This will be assessed via the endurance shuttle walk test, a standardized externally controlled constant paced field test at 85% of the pre-determined maximal velocity (evaluated by the incremental shuttle walk test) until exhaustion.